突破性生物传感器颠覆慢性阻塞性肺病管理

伦德奎斯特研究所的一个研究团队获得了超过 260 万美元的四年资助，用于创建一种可穿戴生物传感器，该传感器可以持续分析汗液，以监测慢性阻塞性肺病患者的急性加重风险。该项目由 Harry Rossiter 博士领导，与加州理工学院合作，旨在通过汗液生物标志物分析来识别病情加重的早期预警信号，这可能会彻底改变慢性阻塞性肺病的管理，并将可穿戴电子产品整合到慢性病护理中。

Pioneering Biosensor to Revolutionize COPD Management

开创性生物传感器彻底改变慢性阻塞性肺病 (COPD) 管理

A groundbreaking research team at The Lundquist Institute has secured a substantial four-year grant from the U.S. Army Medical Research Acquisition Activity, supported by the U.S. Department of Defense’s Peer Reviewed Medical Research Program, to develop a transformative wearable biosensor for chronic obstructive pulmonary disease (COPD). This groundbreaking technology aims to continuously monitor the risk of acute exacerbations, paving the way for real-time disease management and improved patient outcomes.

伦德奎斯特研究所的一个开创性研究团队已从美国陆军医学研究采购活动获得了一笔为期四年的巨额资助，该项目得到了美国国防部同行评审医学研究计划的支持，旨在开发一种用于慢性阻塞性肺疾病的变革性可穿戴生物传感器。慢性阻塞性肺病）。这项突破性技术旨在持续监测急性加重的风险，为实时疾病管理和改善患者治疗结果铺平道路。

Collaborative Innovation for Patient Empowerment

为患者赋权的协作创新

The project, led by Harry Rossiter, PhD, a TLI investigator and professor of respiratory and critical care physiology and medicine at the David Geffen School of Medicine at the University of California, Los Angeles, is a testament to the power of collaboration. Joining forces with Wei Gao, PhD, a materials scientist and engineer at the California Institute of Technology (Caltech), the team is harnessing their expertise to create a wearable biosensor that will empower COPD patients with critical health insights.

该项目由 TLI 研究员、加州大学洛杉矶分校大卫格芬医学院呼吸和重症监护生理学和医学教授 Harry Rossiter 博士领导，证明了合作的力量。该团队与加州理工学院 (Caltech) 的材料科学家兼工程师 Wei Gau 博士联手，利用他们的专业知识创建一种可穿戴生物传感器，为慢性阻塞性肺病 (COPD) 患者提供重要的健康见解。

Early Detection, Proactive Intervention

早期发现，主动干预

COPD, a debilitating condition that affects millions worldwide, is characterized by chronic inflammation in the lungs that obstructs airflow. While there is currently no cure for COPD, early detection of acute exacerbations, or flares, is crucial for preventing serious health complications.

慢性阻塞性肺病是一种使人衰弱的疾病，影响着全世界数百万人，其特点是肺部慢性炎症阻碍气流。虽然目前慢性阻塞性肺病无法治愈，但早期发现急性加重或发作对于预防严重的健康并发症至关重要。

The wearable biosensor being developed by Rossiter and Gao will continuously analyze sweat for telltale signs of an impending flare. By identifying these early biomarkers, the sensor will provide real-time guidance on disease management, eliminating the need for frequent blood tests and enabling proactive interventions.

罗西特和高正在开发的可穿戴生物传感器将持续分析汗液，以发现即将爆发的迹象。通过识别这些早期生物标志物，传感器将为疾病管理提供实时指导，消除频繁血液检测的需要并实现主动干预。

Non-Invasive Monitoring for Improved Health

无创监测改善健康

"The proposed sensor has the potential to revolutionize COPD management but also to impact healthcare by incorporating wearable electronics into chronic disease management," said Rossiter. "Our ultimate goal is to develop a wearable system to preempt [acute exacerbations], providing an early warning system to move treatment earlier in the exacerbation process and thereby reduce patient morbidity, mortality, hospitalization, and healthcare utilization."

罗西特说：“所提出的传感器有可能彻底改变慢性阻塞性肺病的管理，而且还可以通过将可穿戴电子设备纳入慢性病管理来影响医疗保健。” “我们的最终目标是开发一种可穿戴系统来预防[急性加重]，提供早期预警系统，以便在急性加重过程中尽早进行治疗，从而降低患者的发病率、死亡率、住院率和医疗保健利用率。”

The biosensor, worn as a patch, will measure C-reactive protein levels in sweat, an inflammatory marker that can differentiate between mild and moderate flares. The grant will support the development of a more sophisticated sensor capable of measuring multiple molecules in sweat, enhancing its predictive power.

这种生物传感器作为贴片佩戴，将测量汗液中的 C 反应蛋白水平，这是一种炎症标记物，可以区分轻度和中度炎症。这笔赠款将支持开发一种更复杂的传感器，能够测量汗液中的多个分子，从而增强其预测能力。

Transforming Healthcare through Wearable Technology

通过可穿戴技术改变医疗保健

"In partnership with Dr. Harry Rossiter and The Lundquist Institute, our team at Caltech is advancing medical technology with wearable biosensors," said Gao. "Our aim with this project is to transform chronic disease management and push healthcare towards continuous, non-invasive monitoring for better health."

“我们加州理工学院的团队与 Harry Rossiter 博士和伦德奎斯特研究所合作，正在利用可穿戴生物传感器推进医疗技术，”高说。 “我们这个项目的目标是改变慢性病管理，推动医疗保健走向持续、非侵入性监测，以改善健康状况。”

The Lundquist Institute, a renowned biomedical research organization affiliated with the University of California, Los Angeles, is committed to developing innovative solutions for complex health challenges. Their collaboration with Caltech underscores the transformative potential of wearable technology in improving the lives of those living with chronic conditions.

伦德奎斯特研究所是隶属于加州大学洛杉矶分校的著名生物医学研究机构，致力于开发针对复杂健康挑战的创新解决方案。他们与加州理工学院的合作强调了可穿戴技术在改善慢性病患者生活方面的变革潜力。

Empowering Patients, Improving Outcomes

赋予患者权力，改善结果

By empowering patients with real-time monitoring and proactive treatment strategies, the wearable biosensor developed by Rossiter and Gao has the potential to revolutionize COPD management. By reducing the risk of acute exacerbations, improving overall health outcomes, and reducing healthcare utilization, this groundbreaking technology promises to transform the lives of countless COPD patients.

Rossiter 和高开发的可穿戴生物传感器通过为患者提供实时监测和主动治疗策略，有可能彻底改变慢性阻塞性肺病的管理。通过降低急性加重的风险、改善整体健康结果并减少医疗保健利用率，这项突破性技术有望改变无数慢性阻塞性肺病患者的生活。